[go: up one dir, main page]

IN2014DN09347A - - Google Patents

Info

Publication number
IN2014DN09347A
IN2014DN09347A IN9347DEN2014A IN2014DN09347A IN 2014DN09347 A IN2014DN09347 A IN 2014DN09347A IN 9347DEN2014 A IN9347DEN2014 A IN 9347DEN2014A IN 2014DN09347 A IN2014DN09347 A IN 2014DN09347A
Authority
IN
India
Prior art keywords
compounds
disorders
substituents
useful
formula
Prior art date
Application number
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014DN09347A publication Critical patent/IN2014DN09347A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis
IN9347DEN2014 2012-06-20 2013-06-17 IN2014DN09347A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
IN2014DN09347A true IN2014DN09347A (en) 2015-07-17

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9347DEN2014 IN2014DN09347A (en) 2012-06-20 2013-06-17

Country Status (22)

Country Link
US (1) US20150259295A1 (en)
EP (1) EP2864294A1 (en)
JP (1) JP2015520201A (en)
KR (1) KR20150011003A (en)
CN (1) CN104411690A (en)
AU (1) AU2013279510A1 (en)
BR (1) BR112014031108A2 (en)
CA (1) CA2869602A1 (en)
CL (1) CL2014003242A1 (en)
CO (1) CO7160077A2 (en)
CR (1) CR20140516A (en)
EA (1) EA201492283A1 (en)
HK (1) HK1206341A1 (en)
IL (1) IL236091A0 (en)
IN (1) IN2014DN09347A (en)
MA (1) MA37765A1 (en)
MX (1) MX2014014105A (en)
PE (1) PE20142445A1 (en)
PH (1) PH12014502364A1 (en)
SG (1) SG11201407229UA (en)
UA (1) UA109867C2 (en)
WO (1) WO2013189862A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014011555A (en) 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
JP6579103B2 (en) 2014-06-27 2019-09-25 宇部興産株式会社 Salts of halogen-substituted heterocyclic compounds
AU2018388482A1 (en) * 2017-12-19 2020-07-30 Bristol-Myers Squibb Company Pyrazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CN111434655A (en) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 Lysophosphatidic acid receptor antagonists and process for their preparation
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI843503B (en) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa receptor antagonists and uses thereof
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022240879A1 (en) * 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240115978A (en) 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 LPA receptor antagonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249154A1 (en) * 2003-12-26 2008-10-09 Ono Pharmaceutical Co., Ltd. Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
CN102574822A (en) * 2009-08-04 2012-07-11 阿米拉制药公司 Compounds as lysophosphatidic acid receptor antagonists
AU2011338561A1 (en) * 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
SG2014011555A (en) * 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
HK1206341A1 (en) 2016-01-08
PE20142445A1 (en) 2015-01-28
BR112014031108A2 (en) 2017-06-27
PH12014502364A1 (en) 2015-01-12
CL2014003242A1 (en) 2015-03-20
MX2014014105A (en) 2015-03-05
UA109867C2 (en) 2015-10-12
US20150259295A1 (en) 2015-09-17
EA201492283A1 (en) 2015-04-30
CO7160077A2 (en) 2015-01-15
CA2869602A1 (en) 2013-12-27
JP2015520201A (en) 2015-07-16
IL236091A0 (en) 2015-02-01
WO2013189862A1 (en) 2013-12-27
AU2013279510A1 (en) 2014-10-16
MA37765A1 (en) 2017-04-28
CR20140516A (en) 2014-12-01
EP2864294A1 (en) 2015-04-29
SG11201407229UA (en) 2014-12-30
KR20150011003A (en) 2015-01-29
CN104411690A (en) 2015-03-11

Similar Documents

Publication Publication Date Title
IN2014DN09352A (en)
IN2014DN09348A (en)
IN2014DN09347A (en)
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
IN2014DN09434A (en)
IN2014MN02598A (en)
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
IN2015DN01119A (en)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
MX2016002794A (en) Antiproliferative compounds.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
IN2014DN06869A (en)
MX340574B (en) Imidazo pyrazines.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
MX2015001657A (en) Lpar - substituted cyanopyrazole compounds.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2015002755A3 (en) Compounds for the treatment of malaria
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions